Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients with Hematological Malignancies and Subjected to Treatment with Immune-checkpoint Inhibitors (Endemato)

Scientific Institute for Research Hospitalization and Healthcare (IRCCS)

Status: Enrolling

Conditions: Hematological Malignancies

Study type: Observational

Funder types: Other

Identifiers

NCT06851702

Endemato

Details and patient eligibility

About

Retrospective / prospective observational study of endocrinological adverse events in hematologic patients treated with immunological checkpoint inhibitors

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Retrospective cohort

• patients aged> 18 years
• cyto-histological diagnosis of mature lymphoproliferative syndrome of B or T lymphocyte origin
• advanced stage of illness (relapsed or refractory)
• patients undergoing treatment with immune anticheckpoint antibodies.
• written informed consent

Prospective cohort

• patients aged> 18 years
• cyto-histological diagnosis of mature lymphoproliferative syndrome of B or T lymphocyte origin
• advanced stage of illness (relapsed or refractory)
• patients who are candidates for therapy with anticheckpoint immune antibodies (it is specified that this therapy is completely independent of the subject's participation in the study).
• written informed consent

Exclusion criteria

• Severe, acute and chronic medical or psychiatric disorders that may affect the interpretation of the study results or interfere with it.